Literature DB >> 6978717

Histone antibodies in systemic lupus erythematosus. A possible diagnostic tool.

M Gioud, M A Kaci, J C Monier.   

Abstract

Antibodies to total histones and histone fractions H1, H2a-H4, H2b, and H3 were measured in serum samples from 61 patients with systemic lupus erythematosus (SLE), 33 with rheumatoid arthritis, 17 with systemic sclerosis, and 20 with various other diseases by use of a sensitive immunoenzymatic assay. Histone antibodies were present in 52.4% of the SLE samples whereas only 1 of the samples from other diseases was positive (systemic sclerosis). The presence of these antibodies in SLE patients was not associated with any specific clinical manifestations, but was correlated with activity of the disease: 87% (20 of 23) of patients with active SLE, in particular 9 of 9 not yet treated, showed histone antibody whereas only 18% (4 of 22) of samples from patients with inactive SLE were positive. We believe that the measurement of histone antibodies would be a useful addition to the present laboratory parameters (antinuclear and double-stranded DNA antibodies and circulating immune complexes) for the diagnosis and progression of systemic lupus erythematosus, particularly since they seem to appear during or just before the onset of an active phase and tend to be absent during remission.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978717     DOI: 10.1002/art.1780250408

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

Review 1.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 2.  Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus.

Authors:  G Q Shen; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion.

Authors:  J T Hardee; C A Roldan; T W Du Clos
Journal:  West J Med       Date:  1997-08

Review 4.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

5.  Individual variation in the isotype profile of anti-histone autoantibodies in systemic lupus erythematosus.

Authors:  G Fellows; N Gittoes; D G Scott; J S Coppock; A Wainwright; M Goodall; B M Turner
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

6.  Anti-histone antibodies (ELISA and immunoblot) in canine lupus erythematosus.

Authors:  A Brinet; C Fournel; J R Faure; C Venet; J C Monier
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

7.  Relationship of age and sex to autoantibody expression in MRL-+/+ and MRL-lpr/lpr mice: demonstration of an association between the expression of antibodies to histones, denatured DNA and Sm in MRL-+/+ mice.

Authors:  M G Cohen; K M Pollard; L Schrieber
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 8.  Drug-induced lupus.

Authors:  E J Price; P J Venables
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

9.  Enzyme-linked immunosorbent assays for antibodies to poly(A), poly dAT and histones: possibly useful tools for the evaluation of prognosis and disease activity in systemic lupus erythematosus.

Authors:  T Helve; M Gripenberg; P Kurki; A M Teppo; O Wegelius
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

10.  Antibodies to histones in systemic lupus erythematosus: prevalence, specificity, and relationship to clinical and laboratory features.

Authors:  M G Cohen; K M Pollard; J Webb
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.